Display options
Cite
Biltaji E, Yoo M, Jennings BT, et al. Outcomes Associated with Pharmacist-Led Diabetes Collaborative Drug Therapy Management in a Medicaid Population. J Pharm Health Serv Res. 2016;8(1):59-62doi: 10.1111/jphs.12162.
Biltaji, E., Yoo, M., Jennings, B. T., Leiser, J. P., & McAdam-Marx, C. (2017). Outcomes Associated with Pharmacist-Led Diabetes Collaborative Drug Therapy Management in a Medicaid Population. Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain, 8(1), 59-62. https://doi.org/10.1111/jphs.12162
Biltaji, Eman, et al. "Outcomes Associated with Pharmacist-Led Diabetes Collaborative Drug Therapy Management in a Medicaid Population." Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain vol. 8,1 (2017): 59-62. doi: https://doi.org/10.1111/jphs.12162
Biltaji E, Yoo M, Jennings BT, Leiser JP, McAdam-Marx C. Outcomes Associated with Pharmacist-Led Diabetes Collaborative Drug Therapy Management in a Medicaid Population. J Pharm Health Serv Res. 2017 Mar;8(1):59-62. doi: 10.1111/jphs.12162. Epub 2016 Dec 19. PMID: 28630653; PMCID: PMC5473652.
Copy Download .nbib Format: NLM
Share it on

J Pharm Health Serv Res. 2017 Mar;8(1):59-62. doi: 10.1111/jphs.12162. Epub 2016 Dec 19.

Outcomes Associated with Pharmacist-Led Diabetes Collaborative Drug Therapy Management in a Medicaid Population.

Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain

Eman Biltaji, Minkyoung Yoo, Brandon T Jennings, Jennifer P Leiser, Carrie McAdam-Marx

Affiliations

  1. Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, University of Utah, 30 S. 2000 E., Salt Lake City, UT 84112, 801 585 1065, [email protected].
  2. Department of Economics, University of Utah, 332 S 1400 E, Salt Lake City, UT 84112, 801 581 7481, [email protected].
  3. Department of Pharmacy Practice, Shenandoah University Bernard J. Dunn School of Pharmacy, 1460 University Drive, Winchester, VA 22601, 540 665 1282, [email protected].
  4. Department of Family & Preventive Medicine, 375 Chipeta Way Rm 201, Salt Lake City, UT 84108, 801 581 7961, [email protected].
  5. Department of Pharmacotherapy, University of Utah, 30 S. 2000 E., Salt Lake City, UT 84112, 801 587 7728, [email protected].

PMID: 28630653 PMCID: PMC5473652 DOI: 10.1111/jphs.12162

Abstract

OBJECTIVES: Pharmacist-led diabetes collaborative drug therapy management (CDTM) has been shown to improve outcomes. Whether such programs are effective specifically in Medicaid patients, who face barriers to access and self-management, has not been well characterized. This pilot study explores glycemic control, utilization and costs associated with pharmacist-led CDTM in a small population of Medicaid patients with type 2 diabetes mellitus (T2DM).

METHODS: A pre-post, historical cohort study was conducted of patients with T2DM and Medicaid coverage who received pharmacist-led CDTM in community-based primary clinics between 2008-2012. Outcomes included change in HbA1c, healthcare costs and utilization.

RESULTS: This study included 79 Medicaid patients with T2DM who received pharmacist-led CDTM. A subset of 46 patients with Medicaid coverage through an affiliated Medicaid Plan, Healthy U, was identified for additional analysis. At 6-months follow-up, HbA1c was a mean (SD) of 2.0% (2.0) lower than the baseline of 10.3% (1.7). Primary care clinic encounters increased by a mean (median) of 3.4 (2) visits. Per patient health system charges increased by a mean (median) of $4,392 ($620) and the amount paid by Medicaid in the Healthy U subset was $822 ($68) higher in the follow-up period.

CONCLUSION: A pharmacist-led diabetes CDTM intervention was associated with improved glycemic control in Medicaid patients, which corresponded with a higher number of primary care visits and observed costs. These findings are consistent with studies not limited to Medicaid, suggesting that CDTM can be effective in type 2 diabetes patients with Medicaid coverage.

Keywords: Type 2 diabetes; clinical pharmacy service; costs; disparity

Conflict of interest statement

Conflicts of Interest. None to report.

References

  1. Am J Health Syst Pharm. 2012 Nov 15;69(22):1951-3 - PubMed
  2. Med Care. 2014 Aug;52(8):720-7 - PubMed
  3. J Manag Care Spec Pharm. 2014 Sep;20(9):914-9 - PubMed
  4. J Manag Care Spec Pharm. 2015 Jun;21(6):452-68 - PubMed

Publication Types

Grant support